SCHEMBL4096725

SCHEMBL4096725

COC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS3 P17931 1/20 0.44
CA1 P00915 5/20 0.41
CA2 P00918 5/20 0.41
CA9 Q16790 5/20 0.41
PYGB P11216 1/20 0.37
AHCY P23526 1/20 0.37
CYP2C19 P33261 1/20 0.35
CA12 O43570 3/20 0.33
PPM1B O75688 1/20 0.33
PTPN1 P18031 1/20 0.33
PPP1CC P36873 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
ITGA4 P13612 1/20 0.33
CA14 Q9ULX7 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107459 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL30353978 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL26243844 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL12085049 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL1811839 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL185267 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL30660898 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL12082047 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL7154268 1.00 LGALS3 (0.44) LGALS3CA1CA2CA9PYGB
SCHEMBL29065825 0.98 LGALS3 (0.43) LGALS3CA1CA2CA9PYGB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119015137-A Nanometer microemulsion and preparation method and application thereof 广州真极和美生物科技有限公司 2024-11-26 CN claimed
EP-4157853-B1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS GIIANT PHARMA INC (CA) 2024-07-31 EP claimed
CN-115505020-B Ursolic acid saponin and its preparation method and use 沈阳药科大学 2023-09-12 CN claimed
US-20230250123-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS GIIANT PHARMA INC. (CA) 2023-08-10 US claimed
CN-116056713-A Intestinal microbiota bioactive PDE4 inhibitor precursors 吉安特制药公司 2023-05-02 CN claimed
EP-4157853-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS Giiant Pharma Inc. (CA) 2023-04-05 EP claimed
WO-2023040733-A1 BAICALEIN DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国科学院上海药物研究所 2023-03-23 WO claimed
WO-2022048529-A1 FORSYTHIAE FRUCTUS COMPONENT AND OPTIONAL GINSENG COMPONENT, AND USE THEREOF 大连富生天然药物开发有限公司 2022-03-10 WO claimed
CN-113980931-A Application of glucuronic acid hydrolase and mutant thereof in preparation of oleanolic acid-beta-D-glucopyranosyl ester 上海中医药大学 2022-01-28 CN claimed
WO-2021237364-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS GIIANT PHARMA INC. (CA) 2021-12-02 WO claimed
CN-108409815-B Indole glycoside substrate, preparation method and application in aerobic flora vaginitis detection 郑州安图生物工程股份有限公司 2021-08-03 CN claimed
CN-108883069-B Esterification/saponification based process for micro-lipid loading 中央研究院 2021-07-20 CN claimed
CN-106279318-B The separation method and flavone composition of flavone compound in calamint 中国医学科学院药用植物研究所 2019-05-03 CN claimed
CN-108129530-A Detect substrate of β-D-Glucose aldehyde neuraminidase and preparation method thereof and kit 广东优尼德生物科技有限公司 2018-06-08 CN claimed
CN-106727508-A A kind of combination drug for treating chronic dysentery 郑州掌盟网络科技有限公司 2017-05-31 CN claimed
CN-106581025-A Composite western medicine for treating chronic dysentery 郑州仁宏医药科技有限公司 2017-04-26 CN claimed
CN-106511440-A Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof 郑州仁宏医药科技有限公司 2017-03-22 CN claimed
EP-0511917-B1 Glycosylated prodrugs, process for their preparation and uses thereof HOECHST SA LAB (FR) 1996-10-23 EP claimed
US-5561119-A ANTITUMOR AGENTS LABORATOIRES HOECHST (FR) 1996-10-01 US claimed
US-4683222-A STIMULANTS FOR IMMUNE SYSTEM BAYER AKTIENGESELLSCHAFT (DE) 1987-07-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250123-A1 GUT MICROBIOTA BIOACTIVATED PDE4 INHIBITOR PRECURSORS PDE4A, PDE4B, PDE4C LGALS3 2721/4885CA1 2419/4885CA2 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.